Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 2 Combination Trial of IDE397, A Potential First in Class MAT2A Inhibitor, and Trodelvy R in MTAP Deletion Non Small Cell Lung Cancer